Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers
Impact in
- Oncology 740
Classified as
- Journal
- Nature Medicine
In The Last Decade
doi.org/10.1038/nm.2000 →Countries where authors are citing Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers
This map shows the geographic impact of Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers more than expected).
Fields of papers citing Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers
This network shows the impact of Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.
About Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers
This paper, published in 2009, received 1.0k indexed citations . Written by Elgene Lim, François Vaillant, Di Wu, Natasha C. Forrest, Bhupinder Pal, Adam H. Hart, Marie-Liesse Asselin-Labat, David Gyorki, Teresa Ward and Frank Feleppa covering the research area of Genetics, Oncology and Molecular Biology. It is primarily cited by scholars working on Oncology (740 citations), Molecular Biology (645 citations), Cancer Research (382 citations), Genetics (207 citations) and Pulmonary and Respiratory Medicine (104 citations). Published in Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/10.1038/nm.2000.